INFLUENZA A VIRUS VARIANTS Russian patent published in 2021 - IPC C07K14/05 C12N7/00 C12N9/12 C12N15/63 C12Q1/6876 G01N33/50 

FIELD: virology.

SUBSTANCE: invention relates to the isolated polynucleotide of the influenza A virus. The isolated influenza A virus polynucleotide encoding the PB2 polymerase mutant of influenza A virus is proposed, wherein the PB2 polymerase mutant contains the amino acid sequence SEQ ID NO: 1 with the substitution of one amino acid selected from the group consisting of: Q306H, Q306L, F323S, F323Y, S324G, S324I, S324N, S324R, S337L, S337P, F363L, K376N, K376Q, K376R, F404Y, M431I, M431T, N510K and N510T. Also proposed is a nucleotide probe capable of hybridization under severe conditions with the specified polynucleotide, an expression system including a plasmid that contains the specified virus polynucleotide, or that contains a vector including the specified polynucleotide functionally associated with the promoter. A host cell transfected, transformed, or transduced by the specified vector is also proposed. The specified polynucleotide is used for obtaining an immunogenic composition for prevention or treatment of influenza A virus infection. Also, the specified polynucleotide can be used in a method for assessing resistance to a drug of the influenza A virus containing a PB2 polymerase mutant, a method for identifying in vitro a candidate compound for treating an infection caused by the influenza A virus in a patient, and a method for identifying in vitro a candidate compound for treating or preventing an infection caused by the influenza A virus in a patient.

EFFECT: invention can be used to create new antiviral therapeutic agents effective against the specified mutated influenza A viruses.

24 cl, 5 tbl, 9 ex